阿尔茨海默病试验正转向受癌症研究启发的多靶点方法，即便Novo Nordisk的司美格鲁肽试验失败。只有两种药物——Eli Lilly的Kisunla和Eisai与Biogen的Leqembi——被广泛批准用于减缓疾病进展。这种演变将这种脑部退化疾病视为复杂系统，在其全球影响下寻求新的遏止途径。
阿尔茨海默病导致全球超过5500万痴呆病例中的约60%，其特征是大脑中淀粉样蛋白和tau蛋白积聚。
目前仅有两种药物被广泛批准用于减缓其进展：Eli Lilly的Kisunla和Eisai与Biogen的Leqembi。这两种药物通过清除有毒的淀粉样蛋白斑块，将进展速度降低约30%。
专家们强调试验中的关键转变，例如Novo Nordisk的重磅GLP-1药物司美格鲁肽用于阿尔茨海默病的试验失败。这些努力凸显了将这种脑部退化疾病视为复杂通路网络的观点，类似于癌症治疗领域的近期变革。
借鉴癌症的多靶点策略，研究人员正在推进工作，以识别更多靶点和方法，更全面地阻断该疾病。
由 AI 报道 AI 生成的图像 事实核查
Researchers at Osaka Metropolitan University report that while the Alzheimer’s drug lecanemab reduces amyloid plaques, MRI measures found no improvement in the brain’s glymphatic waste-clearance three months after treatment began, underscoring the disease’s complexity and the need for multi-target approaches.
Brazil's National Health Surveillance Agency (Anvisa) approved the drug lecanemabe, marketed as Leqembi, on Thursday, January 8, for patients with early-stage Alzheimer's. The monoclonal antibody, administered via infusion, slows disease progression in individuals with mild cognitive impairment and confirmed beta-amyloid protein in the brain. The approval marks progress, though it is not a cure.
由 AI 报道
中国生物技术公司SciNeuro制药与瑞士制药巨头诺华周一宣布达成一项价值近17亿美元的合作协议，旨在开发治疗阿尔茨海默病的药物，该病影响全球约5500万人。 该协议授予诺华独家全球权利，开发和商业化SciNeuro的抗体候选物，以针对这种进行性脑部疾病。 SciNeuro的新型淀粉样蛋白β靶向抗体项目利用专有血脑屏障穿梭技术，帮助更多药物进入大脑发生阿尔茨海默病损伤的区域。
Researchers from MIT and Stanford University have developed multifunctional molecules called AbLecs to block sugar-based immune checkpoints on cancer cells. This approach aims to enhance immunotherapy by allowing immune cells to better target tumors. Early tests in cells and mice show promising results in boosting anti-tumor responses.
由 AI 报道
Prof KVS Hari, director of the Centre for Brain Research at IISc Bengaluru, emphasized digital biomarkers for early detection and prevention of dementia. He noted that India's rapidly aging population makes dementia a major public health challenge. The centre focuses on data collection and AI to understand disease progression in the Indian context.
Scientists at Northwestern Medicine have developed an antibody that counters pancreatic cancer's sugar-based disguise, enabling the immune system to attack tumors more effectively. In mouse studies, the therapy slowed tumor growth by restoring immune activity. The team is preparing the antibody for human trials.
由 AI 报道 事实核查
Researchers led by Mass General Brigham and the Technical University of Munich report that tirzepatide and semaglutide are associated with significant reductions in heart attacks, strokes and death among adults with type 2 diabetes at elevated cardiovascular risk. Drawing on nearly one million insurance records, the Nature Medicine analysis finds strong and early heart protection from both GLP‑1–based drugs, with only modest differences between them.